Stock Watch: The Biotech Departure Lane From Europe

Exacting European Reimbursement Systems Cannot Be Mastered Without Outcomes Evidence

It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

bluebird bio is not the first company to give up on commercializing its product in the fragmented, single payer and price-sensitive markets of Europe. Underestimating the challenges of the European market and failing to commercialize approved products should be recognized as a corporate weakness.

Gene therapy company bluebird’s recent European exit after failing to agree a price in Germany for its one-and-done treatment Zynteglo...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip